Drug discovery

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Last chance to register: Generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#2025 predictions #Artificial intelligence (AI) #Drug discovery #Lab technology #Machine learning

Tech, ML and AI: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Here, the focus is on technology, machine learning (ML) and artificial intelligence (AI). In a prediction piece written for Forbes, contributor Bernard Marr outlined five key technology trends for 2025 across multiple industries1. With… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

#Drug discovery

Whitepaper: Accelerating CMC Strategies for Fab and Fc-Fusion Protein Development

Download the whitepaper to learn more about: Comprehensive CMC Solutions: Explore integrated Chemistry, Manufacturing, and Controls (CMC) strategies tailored to the unique challenges of Fab and Fc-Fusion protein development. Overcoming Complexity: Learn how flexible approaches can streamline the development of complex protein formats, ensuring robust and scalable manufacturing processes. Read More

#Whitepapers

Next generation sequencing
#Advertorial #Drug discovery #Next generation sequencing

How fast nucleic acid quantification and purity assessment support NGS

This advertorial for BMG Labtech appeared in DDW Volume 26 – Issue 1, Winter 2024/25 Read the digital issue Next generation sequencing (NGS) is driving advances in the life sciences including the detection of disease-causing mutations. However, the downstream quantification of nucleic acids and purity assessment remain vital for success. Read More

#Exclusive Content

#Drug discovery

Whitepaper: Standardising Data: Why do it and how?

Standardisation is critical to extracting the full potential of analytical data—in facilitating data-driven science and AI/ML-powered innovation. This whitepaper will help you: Review currently available standard formats Understand the pros and cons of open and proprietary formats Ensure data is adequately prepared for scientists and AI/ML applications… Read More

#Whitepapers

Neurons in a brain with Alzheimer's disease
#Drug discovery #Mission Therapeutics #Mitophagy #Neurodegenerative disorders #Neuroscience

Can neurodegenerative diseases be tackled by enhancing mitophagy?

Mission Therapeutics, a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, has announced the publication of a review article titled ‘Targeting mitophagy in neurodegenerative diseases’ in the journal Nature Reviews Drug Discovery. The article outlines the progress scientists have made in identifying that mitochondrial dysfunction is… Read More

#News

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Webinar covers the benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#Cancer drug targets #Collaboration #Drug discovery #Molecular glue degrader #Protein #Rappta Therapeutics #SpringWorks Therapeutics

License agreement for molecular glue targeting PP2A

Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More

#Business & Investment #Cancer Research #News

#Drug discovery #High throughput screening #Omics #Transcriptomics

Company achieves breakthrough in transcriptomic drug discovery

QUANTRO Therapeutics has successfully completed its first 10-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets.   After establishing its technology for single- and dual-target screenings at a current capacity of approximately one million compounds per year, QUANTRO has… Read More

#News

Molecules
#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Learn about the benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News

#Drug development #Drug discovery

Hot off the press: DDW Winter issue out now

The Winter issue of Drug Discovery World (DDW) is out now and asks why sex and gender need to be recognised in drug discovery.  Read the digital version free here.  Other features in the Winter issue include:  How to prepare for the… Read More

#News

#Clinical trials #CNS #Drug development #Drug discovery #Rare disease

The difficulties of rare disease clinical trials

Late-stage biotech Minoryx is developing a therapy (leriglitazone) targeting patients with the rare progressive CNS disease cerebral adrenoleukodystrophy (cALD). If approved, it would give patients another choice of treatment options outside of stem cell transplants and gene therapies. Data presented last year for leriglitazone showed it stopped cALD disease progression… Read More

#Exclusive Content

#Astex Pharmaceuticals #Bioorthogonal chemistry #Click chemistry #Cognitive impairment #Covid-19 #Drug discovery #Life sciences #Long Covid #Molecular Biology #Neuroscience #Public health

Podcast: Innovative approaches to improving drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down… Read More

#News

#Artificial intelligence (AI) #Drug development #Drug discovery #Omics #RNA

Omics, mRNA and AI: Your top 10 reads of 2024

What were the trending topics of the year? Here, we run through DDW’s most read articles of 2024. 10: The future outlook for mRNA therapies In this article for the Spring 2024 issue, DDW Editor Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. 9: Key… Read More

#News

#AI / data analytics / healthtech / informatics #Amazon Web Services (AWS) #Artificial intelligence (AI) #Drug development #Drug discovery #Generative AI

Webinar: The benefits of generative AI in drug discovery

In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More

Webinar date:
Supported by Amazon Web Services and NVIDIA
#News